Everest medicines announces Taiwan TFDA approval of NEFECON® for the treatment of Primary IgA Nephropathy
October 21, 2024 | 06:40
Everest Medicines, a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announces that the Taiwan Food and Drug Administration has approved NEFECON® indicated "to reduce the loss of kidney function in adult patients with primary immunoglobulin A nephropathy who are at risk for disease progression".
Mobile Version